


Aldosterone

Cat. No.:	HY-113313		
CAS No.:	52-39-1		
Molecular Formula:	C ₂₁ H ₂₈ O ₅		
Molecular Weight:	360.44		
Target:	Endogenous Metabolite		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (277.44 mM; Need ultrasonic)
Ethanol : 33.33 mg/mL (92.47 mM; Need ultrasonic)

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.7744 mL	13.8719 mL	27.7439 mL
	5 mM	0.5549 mL	2.7744 mL	5.5488 mL
	10 mM	0.2774 mL	1.3872 mL	2.7744 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution
- Add each solvent one by one: 10% EtOH >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Aldosterone is the primary mineralocorticoid. Aldosterone is a steroid hormone, and it is synthesized and secreted in response to renin-angiotensin system activation (RAS) or high dietary potassium by the zona glomerulosa (ZG) of the adrenal cortex. Aldosterone activity is dependent by the binding and activation of the cytoplasmic/nuclear mineralocorticoid receptor (MR) at cellular level ^{[1][2]} .								
IC₅₀ & Target	Human Endogenous Metabolite								
In Vitro	Aldosterone (1-1000 nM; 24 hours) inhibits interleukin-1 β -stimulated nitrite production by vascular smooth muscle cells in a dose-dependent manner ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Aldosterone (1 mg/Kg+1% NaCl; i.h.; once daily for 3 weeks) significantly increases systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular systolic pressure (LVSP) and left ventricular end-diastolic pressure (LVEDP) ^[4] . Aldosterone (0.72 mg/kg/day; 14 days) causes a small increase (14 mmHg) in blood pressure in male mice ^[5] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Forty male Wistar rats^[4]</td> </tr> <tr> <td>Dosage:</td> <td>1 mg/Kg (+1% NaCl)</td> </tr> <tr> <td>Administration:</td> <td>i.h.; once daily for 3 weeks</td> </tr> <tr> <td>Result:</td> <td>Systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular systolic pressure (LVSP) and left ventricular end-diastolic pressure (LVEDP) were significantly higher in aldosterone-salt-treated animals.</td> </tr> </table>	Animal Model:	Forty male Wistar rats ^[4]	Dosage:	1 mg/Kg (+1% NaCl)	Administration:	i.h.; once daily for 3 weeks	Result:	Systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular systolic pressure (LVSP) and left ventricular end-diastolic pressure (LVEDP) were significantly higher in aldosterone-salt-treated animals.
Animal Model:	Forty male Wistar rats ^[4]								
Dosage:	1 mg/Kg (+1% NaCl)								
Administration:	i.h.; once daily for 3 weeks								
Result:	Systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular systolic pressure (LVSP) and left ventricular end-diastolic pressure (LVEDP) were significantly higher in aldosterone-salt-treated animals.								

CUSTOMER VALIDATION

- Nat Chem Biol. 2022 Aug 18.
- Acta Pharmacol Sin. 2022 Sep;43(9):2429-2438.
- J Med Chem. 2022 Nov 18.
- Eur J Med Chem. 2022 Apr 20;237:114382.
- Int J Endocrinol. 2021 Jun 18;2021:5575927.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Nanba K, et al. Aging and Adrenal Aldosterone Production. Hypertension. 2018 Feb;71(2):218-223.
- [2]. Cannavo A, et al. Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology. Oxid Med Cell Longev. 2018 Sep 19;2018:1204598.
- [3]. Ikeda U, et al. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol. 1995 Jul 18;290(2):69-73.
- [4]. Martín-Fernández B, et al. Beneficial effects of proanthocyanidins in the cardiac alterations induced by aldosterone in rat heart through mineralocorticoid receptor blockade. PLoS One. 2014 Oct 29;9(10):e1111104.
- [5]. Dinh QN, et al. Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor. Brain Res. 2016 Apr 15;1637:146-153.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA